The efficacy and safety of MARS-PD: Meridian activation remedy system for Parkinson’s disease—A single-center, assessor and statistician-blinded, parallel-group randomized, controlled trial protocol
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303156 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Miso S Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) patients face a substantial unmet need for disease-modifying interventions. Potential approaches such as exercise and acupuncture have been investigated to slow PD progression. To address this unmet need, we developed a novel therapeutic approach that integrates acupuncture and exercise: the Meridian Activation Remedy System for PD patients (MARS-PD). Building upon promising outcomes observed in our preliminary pilot study, where MARS-PD exhibited a large clinically important difference on the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS Part III), we embark on a randomized controlled trial with the primary objective of examining the efficacy, safety, and economic impact of MARS-PD.
Methods
In this single-center, assessor and statistician-blinded, parallel-group randomized controlled trial, we aim to investigate the clinical efficacy of MARS-PD through 16 interventions administered over 8 weeks in 88 PD patients. Participants will be randomly assigned to the experimental (n = 44) or control (n = 44) groups. The experimental group will receive MARS-PD intervention alongside standard care, while the control group will solely receive standard care. The intervention period spans 8 weeks, followed by a 12-week post-intervention follow-up. The primary endpoint is the change in MDS-UPDRS Part III score from baseline to the conclusion of the 8-week intervention. Secondary outcomes encompass various assessments, including MDS-UPDRS, International Physical Activity Questionnaire Short Form, Parkinson Self Questionnaire, Parkinson’s Disease Sleep Scale, Timed Up and Go test, GAITRite metrics, Functional Near-Infrared Spectroscopy measurements, smart band outcomes, gut microbiome analysis results, and iris connective tissue texture.
Discussion
Previous studies by the authors have indicated MARS-PD’s safety and benefits for PD patients. Building upon this foundation, our current study aims to provide a more comprehensive and detailed confirmation of the efficacy of MARS-PD. Trial registration cris.nih.go.kr KCT0006646 –First posted on 7 October 2021; ClinicalTrials.gov NCT05621772 –First posted on 11 November 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clinical Trial Center, Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.
- Department of Cardiology and Neurology of Korean Medicine, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
- Department of Oriental Neuropsychiatry, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
ORCID-Profile: Miso S Park, SangSoo Park, Jie-Yoon Kang, In Chul Jung, HoRyong Yoo
Förderung
- Korea Health Industry Development Institute
Zitieren
APA
Park, M. S., Park, S., Kang, J. Y., Jung, I. C., & Yoo, H. (2024). The efficacy and safety of MARS-PD: Meridian activation remedy system for Parkinson’s disease—A single-center, assessor and statistician-blinded, parallel-group randomized, controlled trial protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0303156
Vancouver
Park MS, Park S, Kang JY, Jung IC, Yoo H. The efficacy and safety of MARS-PD: Meridian activation remedy system for Parkinson’s disease—A single-center, assessor and statistician-blinded, parallel-group randomized, controlled trial protocol. PLOS ONE. 2024. doi:10.1371/journal.pone.0303156
BibTeX
@article{Park2024,
author = {Park, Miso S and Park, SangSoo and Kang, Jie-Yoon and Jung, In Chul and Yoo, HoRyong},
title = {The efficacy and safety of MARS-PD: Meridian activation remedy system for Parkinson’s disease—A single-center, assessor and statistician-blinded, parallel-group randomized, controlled trial protocol},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303156}
}
EUVIMED